Sign in
Taking people in HungaryPhase 4

Immune system changes in brain cancer patients receiving bevacizumab infusion

Tests how bevacizumab infusion affects the immune system in adults with glioblastoma, a brain cancer.

Key facts

Who runs it
Orszagos Onkologiai Intezet
Where
Budapest XII and Szeged, HungarySee the 2 sites
Registry title
Brain cancer and changes in immune system
Status
Recruiting
Phase
Phase 4
People taking part
175 people, planned
Started
28 Jun 2024
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
28 June 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with glioblastoma multiforme (a brain cancer) who are treated with bevacizumab. It studies changes in the immune system.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Glioblastoma multiforme that has not come back (before radiotherapy and temozolomide), or that has come back after other treatment.
Earlier treatment
People whose cancer came back must already have had other treatment (surgery, radiotherapy and temozolomide). Some people already receiving bevacizumab for a relapse can also join.

Main reasons for not taking part

  • Hypersensitivity to bevacizumab or its excipients, or to CHO cell products or other recombinant human or humanised antibodies
  • History of psychiatric diseases and treatment
  • Another cancer besides glioblastoma multiforme
  • Took part in another clinical trial within the last 3 months
  • Known drug or chronic alcohol abuse

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  •  Not recurrent glioblastoma multiforme patients (either after opus or with no opus) before radiotherapy and temozolomide therapy.  Recurrent patients who have already undergone other therapeutic intervention (surgery, radiotherapy and temozolomide therapy) and due to the recurrence of the disease, based on clinical experience, it is justified to start bevacizumab therapy.  Known relapse patients who are already receiving bevacizumab therapy

Who cannot take part

  •  Unwillingness to sign the written Informed Consent Form.  History of psychiatric diseases and treatment.  Hypersensitivity to the active substance or to any of the excipients.  Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.  Participation in another clinical trial within 3 months prior to this study.  Known drug or chronic alcohol abuse, drug addiction.  Malignant disease other than GBM.  Legal incapacity and/or other circumstances rendering the subject unable to understand the nature, scope and possible consequences of the study.  Evidence of an uncooperative attitude.  Vulnerable subject

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • How old are you?

Where in Hungary

  • Orszagos Onkologiai IntezetBudapest XII, HungaryTaking people
  • University of SzegedSzeged, HungaryTaking people

About the trial

What the trial wants to find out

An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
Plain-language title
Immune system changes in brain cancer patients receiving bevacizumab infusionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-512136-30-00, who can take part
Record updated
28 June 2024